IMV to Provide Updated Data From Phase 2 Study Evaluating DPX-Survivac in Combination with Merck’s Keytruda® in DLBCL
May 03 2019 - 6:05AM
Business Wire
Abstract on the study accepted at the 2019 ICML
Meeting
IMV Inc. (Nasdaq: IMV; TSX: IMV), the clinical stage
immuno-oncology corporation, today announced that the 2019
International Conference on Malignant Lymphoma (ICML) will publish
an abstract on the company’s combination immunotherapy trial
titled, “Phase 2 Study: DPX-Survivac with Intermittent Low Dose
Cyclophosphamide and Pembrolizumab in Patients with
recurrent/refractory Diffuse Large B-Cell Lymphoma – The SPiReL
trial.”
“DLBCL is our first indication for DPX-Survivac in combination
with Merck’s’ Keytruda® (pembrolizumab) and we have been encouraged
by the previously announced early data in this patient population
with rapidly progressing cancer and short life expectancy,” said
Frederic Ors, Chief Executive Officer at IMV. “Given the high level
of unmet need in recurrent/refractory DLBCL, we look forward to
working with our partners at Sunnybrook Research Institute to
provide an update on this important program.”
ICML will publish the full trial-in-progress abstract on June
12, 2019 via the 15-ICML ABSTRACT BOOK, a supplement to
Hematological Oncology. IMV will provide an update on the Phase 2
clinical data related to this study at that time.
About the SPiReL Study
SPiReL (DPX-Survivac with Low Dose
Cyclophosphamide administered with Pembrolizumab in
Patients with persistent or Recurrent/refractory Diffuse Large B-Cell Lymphoma) is a Phase 2
non-randomized, multi-centre, open-label study. Primary
Investigator Neil Berinstein, MD, Affiliate Scientist, Sunnybrook
Research Institute, Professor of Medicine/Immunology, University of
Toronto, is leading the trial, which is expected to enroll 25
evaluable participants whose recurrent DLBCL expresses survivin, a
tumor antigen expressed in approximately 60 percent of DLBCL
patients. The study’s primary endpoint is to document the objective
response rate. Secondary objectives include measuring tumor
regression, and documenting the toxicity profile and durations of
response. In addition, researchers will perform analyses to assess
circulating antigen specific immune responses and changes in
tumor-infiltrating T cell immune responses within the tumor
microenvironment. Investigators also plan to assess potential
biomarkers of immune and clinical response.
About ICML
The International Conference on Malignant Lymphoma (ICML) is
focused on the scientific community involved in the study and
treatment of lymphoid neoplasms. The main aim of ICML is to
facilitate the presentation of the most recent data—basic,
translational and clinical—on lymphoma and encourage the discussion
among hematologists, clinical oncologists, radiation oncologists,
pediatricians, pathologists, and leading researchers from all over
the world.
About IMV
IMV Inc. is a clinical stage biopharmaceutical company dedicated
to making immunotherapy more effective, more broadly applicable,
and more widely available to people facing cancer and other serious
diseases. IMV is pioneering a new class of immunotherapies based on
the Company’s proprietary drug delivery platform. This patented
technology leverages a novel mechanism of action that enables the
programming of immune cells in vivo, which are aimed at
generating powerful new synthetic therapeutic capabilities. IMV’s
lead candidate, DPX-Survivac, is a T cell-activating immunotherapy
that combines the utility of the platform with a target: survivin.
IMV is currently assessing DPX-Survivac as a monotherapy in
advanced ovarian cancer, as well as a combination therapy in
multiple clinical studies with Merck. Connect
at www.imv-inc.com.
IMV Forward-Looking Statements
This press release contains forward-looking information under
applicable securities law. All information that addresses
activities or developments that we expect to occur in the future is
forward-looking information. Forward-looking statements are based
on the estimates and opinions of management on the date the
statements are made. In the press release, such forward-looking
statements include, but are not limited to, statements regarding
the FDA potentially granting accelerated regulatory
approval of DPX-Survivac. However, they should not be regarded as a
representation that any of the plans will be achieved. Actual
results may differ materially from those set forth in this press
release due to risks affecting the Corporation, including access to
capital, the successful design and completion of clinical trials
and the receipt and timely receipt of all regulatory
approvals. IMV Inc. assumes no responsibility to update
forward-looking statements in this press release except as required
by law. These forward-looking statements involve known and unknown
risks and uncertainties and those risks and uncertainties include,
but are not limited to, our ability to access capital, the
successful and timely completion of clinical trials, the receipt of
all regulatory approvals and other risks detailed from time to time
in our ongoing quarterly filings and annual information form
Investors are cautioned not to rely on these forward-looking
statements and are encouraged to read IMV’s continuous disclosure
documents, including its current annual information form, as well
as its audited annual consolidated financial statements which are
available on SEDAR at www.sedar.com and on EDGAR
at www.sec.gov/edgar.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190503005183/en/
MEDIAAndrea Cohen, Sam Brown Inc.O: (917) 209-7163
E: andreacohen@sambrown.comINVESTOR RELATIONSMarc
Jasmin, IMV Senior Director, Investor Relations and
CommunicationsO: (902) 492-1819 ext: 1042M: (514) 917-9481
E: mjasmin@imv-inc.com
IMV (TSX:IMV)
Historical Stock Chart
From Jun 2024 to Jul 2024
IMV (TSX:IMV)
Historical Stock Chart
From Jul 2023 to Jul 2024